Delcath Systems (NASDAQ:DCTH) Sees Large Volume Increase After Analyst Upgrade

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) saw strong trading volume on Wednesday after HC Wainwright raised their price target on the stock from $32.00 to $36.00. HC Wainwright currently has a buy rating on the stock. 569,519 shares traded hands during trading, an increase of 19% from the average daily volume of 477,218 shares. The stock last traded at $21.8080 and had previously closed at $20.10.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen raised Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings lowered Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Zacks Research lowered Delcath Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 6th. Finally, BTIG Research raised their price target on Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a report on Monday. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.33.

Latest Delcath Systems News

Investors following DCTH have been watching these news items:

• Positive Sentiment: Delcath reported quarterly EPS of $0.17, versus analysts’ expected loss, and revenue of $35.1 million, above the $26.0 million consensus. Zacks earnings report
• Positive Sentiment: The company forecast 2026 revenue of $115 million–$117 million, above the $106.2 million analyst consensus, supporting expectations for continued growth. Delcath earnings guidance
• Negative Sentiment: HC Wainwright trimmed its Q2 2027 EPS estimate slightly, to $0.11 from $0.12, a modest offset to its improved longer-term forecasts.

Institutional Trading of Delcath Systems

Institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp purchased a new position in Delcath Systems during the second quarter worth $1,362,000. Allspring Global Investments Holdings LLC bought a new position in Delcath Systems during the 1st quarter valued at about $306,000. Kopp Family Office LLC bought a new position in Delcath Systems during the 3rd quarter valued at about $450,000. Sei Investments Co. grew its holdings in Delcath Systems by 100.0% during the 1st quarter. Sei Investments Co. now owns 44,058 shares of the company’s stock valued at $409,000 after purchasing an additional 22,029 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in Delcath Systems by 31.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock worth $1,417,000 after purchasing an additional 21,069 shares during the period. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems Trading Up 8.0%

The company has a market capitalization of $753.16 million, a PE ratio of 135.66 and a beta of 0.62. The stock’s 50-day moving average is $15.60 and its two-hundred day moving average is $12.54.

Delcath Systems (NASDAQ:DCTH) last announced its earnings results on Monday, November 9th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.26. Delcath Systems had a return on equity of 5.78% and a net margin of 6.05%. The business had revenue of $35.10 million during the quarter, compared to analyst estimates of $25.99 million. On average, equities research analysts forecast that Delcath Systems, Inc. will post -0.17 EPS for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.